Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Gift Nifty was trading around 23,710 level, a premium of nearly 20 points from the Nifty futures’ previous close, indicating ...

ByReuters • Nov 22, 2024 China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug (Reuters) - Eli Lilly (NYSE:LLY) and Hong Kong-listed Laekna will collaborate to ...

Finding stocks with the potential to double in just three years is no easy feat, even in this bull market. Plenty of ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker ... slowdown to a lower-than-expected amount of the drugs in stock at the end of the year and changes to Medicare Part ...

On Tuesday, Deutsche Bank maintained a Hold rating for Eli Lilly and Company (NYSE:LLY) with a price target of $695.00. The stance comes after considering recent Phase 2 trial data ...

Eli Lilly stock rises on upbeat guidance, and Ford Motor’s operating profit forecast disappoints. Honeywell, meanwhile, announces a plan to break up into three companies. Shares of semiconductor ...

Eli Lilly stock rises on upbeat guidance, and Ford Motor’s operating profit forecast disappoints. Honeywell, meanwhile, announces a plan to break up into three companies.

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.